Verrica Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary

Verrica Pharmaceuticals

10/11/2022 13:31

* Verrica Pharmaceuticals Inc  VRCA.OQ  reported quarterly
adjusted earnings of 3 cents​​ per share for the quarter ended
in September. The mean expectation of four analysts for the
quarter was for a loss of 11 cents per share.
    * Revenue was $8.32 million​; analysts expected $4.25
million. 
    * Verrica Pharmaceuticals Inc's reported EPS for the quarter
was
breakeven results​.
    * The mean earnings estimate of analysts had fallen by
about 9.6%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Verrica Pharmaceuticals Inc shares had fallen by 28.4%
this
quarter and lost 77.2% so far this year.
    * The company reported quarterly net income of $83 thousand.
    * Wall Street's median 12-month price target for Verrica
Pharmaceuticals Inc is $11.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
10 at 01:31 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.11          0.03           Beat
 Jun. 30 2022      -0.32          -0.37          Missed
 Mar. 31 2022      -0.47          -0.31          Beat
 Dec. 31 2021      -0.50          -0.35          Beat